ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.

Autor: Ryan, A. J.¹, Wedge, S. R.¹ steve.wedge@astrazeneca.com

Publikováno v: British Journal of Cancer. Jun2005 Supplement, Vol. 92, p6-13. 8p.

Guidelines for the welfare and use of animals in cancer research

Autor: Workman, P., Aboagye, E. O., Balkwill, F., Balmain, A., Bruder, G., Chaplin, D. J., Double, J. A., Everitt, J., Farningham, D. A. H., Glennie, M. J., Kelland, L. R., Robinson, V., Stratford, I. J., Tozer, G. M., Watson, S., Wedge, S. R., Eccles, S. A., Navaratnam, V., Ryder, S., Natl Canc Res Inst, NCRI

Animal experiments remain essential to understand the fundamental mechanisms underpinning malignancy and to discover improved methods to prevent, diagnose and treat cancer. Excellent standards of animal care are fully consistent with the conduct of h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::f0f7f35b897243e494c5d004d999780a

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN™; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts.

Autor: Williams, K. J., Telfer, B. A., Shannon, A. M., Babur, M., Stratford, I. J., Wedge, S. R.

Publikováno v: British Journal of Radiology; Oct2008 Supplement, Vol. 81, pS21-S27, 7p, 1 Color Photograph, 1 Black and White Photograph, 1 Chart, 1 Graph

ZM323881, a Novel Inhibitor of Vascular Endothelial Growth Factor-Receptor-2 Tyrosine Kinase Activity.

Autor: Whittles, C E, Pocock, T M, Wedge, S R, Kendrew, J, Hennequin, L F, Harper, SJ, Bates, D O

Publikováno v: Microcirculation; Dec2002, Vol. 9 Issue 6, p513, 10p